UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.603

Sortiert nach

Nuclear export of proteins and drug resistance in cancer

Biochemical pharmacology, 2012-04, Vol.83 (8), p.1021-1032

2012

Link zum Volltext

Verfügbarkeit prüfen

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4688-4695

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Blood, 2016-05, Vol.127 (21), p.2561-2568

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Journal of clinical oncology, 2008-12, Vol.26 (36), p.5896-5903

2008

Link zum Volltext

Verfügbarkeit prüfen

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner

PloS one, 2015-01, Vol.10 (1), p.e0117693-e0117693

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

Blood, 2008-02, Vol.111 (4), p.2220-2229

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2350-2356

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Journal of hematology and oncology, 2016-08, Vol.9 (1), p.73-11, Article 73

2016

Link zum Volltext

Verfügbarkeit prüfen

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

Cancer research (Chicago, Ill.), 2005-05, Vol.65 (9), p.3815-3822

2005

Link zum Volltext

Verfügbarkeit prüfen

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Blood, 2006-12, Vol.108 (12), p.3881-3889

2006

Link zum Volltext

Verfügbarkeit prüfen

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (17), p.6899-6905

2009

Link zum Volltext

Verfügbarkeit prüfen

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Oncotarget, 2017-06, Vol.8 (26), p.41827-41840

2017

Link zum Volltext

Verfügbarkeit prüfen

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Clinical cancer research, 2009-04, Vol.15 (7), p.2479-2487

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Clinical cancer research, 2007-02, Vol.13 (3), p.986-993

2007

Link zum Volltext

Verfügbarkeit prüfen

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Journal of cellular biochemistry, 2004-05, Vol.92 (2), p.223-237

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Clinical cancer research, 2007-10, Vol.13 (19), p.5855-5861

2007

Link zum Volltext

Verfügbarkeit prüfen

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Journal of Cancer, 2013-01, Vol.4 (8), p.614-625

2013

Link zum Volltext

Verfügbarkeit prüfen

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3200-3209

2010

Link zum Volltext

Verfügbarkeit prüfen

CRM1-mediated nuclear export of proteins and drug resistance in cancer

Current medicinal chemistry, 2008-11, Vol.15 (26), p.2648

2008

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Seminars in cancer biology, 2014-08, Vol.27, p.62-73

2014

Link zum Volltext

Verfügbarkeit prüfen

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues : Implications for drug resistance, tissue-specific expression, and alternative promoter usage

Cancer research (Chicago, Ill.), 2006-05, Vol.66 (10), p.5007-5011

2006

Link zum Volltext

Verfügbarkeit prüfen

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

Molecular cancer therapeutics, 2005-12, Vol.4 (12), p.1993-2000

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2008-03, Vol.14 (5), p.1464-1469

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of indoximod in patients with advanced malignancies

Oncotarget, 2016-04, Vol.7 (16), p.22928-22938

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.603

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.471)
Mit Volltextzugriff
(1.387)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.586)
Japanisch
(282)
Französisch
(13)
Norwegisch
(5)
Latein
(1)
Deutsch
(1)
Persisch
(1)

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.103)
Life Sciences & Biomedicine
(931)
Humans
(791)
Female
(441)
Male
(407)
Adult
(257)
Biological And Medical Sciences
(250)
Middle Aged
(247)
Medical Sciences
(215)
Animals
(196)
Aged
(179)
Oncology
(137)
Physical Sciences
(103)
Child
(100)
Adolescent
(99)
Immunology
(99)
Risk Factors
(94)
Treatment Outcome
(93)
Mice
(87)
Science & Technology - Other Topics
(87)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(44)
Cancer Research
(33)
Clinical Cancer Research
(33)
Science
(31)
The Astrophysical Journal
(26)
The New England Journal Of Medicine
(26)
Nature
(25)
Journal Of Clinical Oncology
(24)
Nature Communications
(17)
Circulation
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Nuclear export of proteins and drug resistance in cancer

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect

CRM1-mediated nuclear export of proteins and drug resistance in cancer

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues : Implications for drug resistance, tissue-specific expression, and alternative promoter usage

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

A phase I study of indoximod in patients with advanced malignancies

Suchergebnisse filtern